The resident immune cells in the brain called microglia, which can damage brain tissue if triggered incorrectly, are the target of many of the immunity-focused Alzheimer’s medicines currently being developed. According to a new study, microglia collaborate with T cells, another form of immune cell, to induce neurodegeneration. (Figure 1).
Researchers found that microglia draw potent cell-killing T cells into the brain of rodents with brain damage similar to Alzheimer’s caused by the protein tau, and that most neurodegeneration could be prevented by preventing the T cells’ entrance or activation. The authors of this research proposed that targeting T cells is an alternative strategy for halting neurodegeneration and treating tauopathies, a group of tau-related illnesses that include Alzheimer’s disease.
There are two major stages to Alzheimer’s development. Amyloid beta protein clumps first start to develop. The plaques may accumulate for many years without having any apparent impacts on mental health. However, ultimately tau also starts to consolidate, indicating that the second phase has begun. The illness then rapidly gets worse from there.
They looked for changes in the immune cell population that take place over the course of the illness in the brains of mice whose immune systems had been genetically altered to imitate various aspects of Alzheimer’s disease in humans. The brains of tau rodents contained significantly more T cells than the brains of amyloid or control mice, according to the experts. In the brains of individuals who had perished from Alzheimer’s disease, T cells were equally prevalent at locations of tau aggregation and neurodegeneration.
Researchers have worked very hard to develop treatments that stop neurotoxicity by influencing tau or microglia. They haven’t, however, examined how we can alter T cells to stop dementia.
Journal article: Chen, X., et al., 2023. Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy. Nature.
Summary by Stefan Botha